Stockscreener 앱 받기
2.10
0.47%
-0.010
시장 영업 전:
2.15
0.05
+2.38%
전일 마감가:
$2.11
열려 있는:
$2.13
하루 거래량:
952.25K
Relative Volume:
0.47
시가총액:
$141.03M
수익:
-
순이익/손실:
$-13.14M
주가수익비율:
-6.8717
EPS:
-0.3056
순현금흐름:
$-13.11M
1주 성능:
+0.00%
1개월 성능:
-12.50%
6개월 성능:
-0.94%
1년 성능:
-16.00%
1일 변동 폭
$2.09
$2.14
1주일 범위
$2.03
$2.2099
52주 변동 폭
$1.6001
$4.67
Microbot Medical Inc Stock (MBOT) Company Profile
명칭
Microbot Medical Inc
전화
908-938-5561
주소
25 RECREATION PARK DR SUITE 108, HINGHAM, MA
Compare MBOT vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBOT
Microbot Medical Inc
|
2.10 | 141.03M | 0 | -13.14M | -13.11M | -0.3056 |
ISRG
Intuitive Surgical Inc
|
451.38 | 159.86B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.17 | 41.01B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
45.32 | 38.32B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
74.45 | 36.29B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
207.88 | 30.15B | 5.40B | 1.49B | 1.78B | 10.12 |
Microbot Medical Inc Stock (MBOT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-10 | 개시 | B. Riley Securities | Buy |
| 2025-12-03 | 개시 | Roth Capital | Buy |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-31 | 개시 | Ladenburg Thalmann | Buy |
Microbot Medical Inc 주식(MBOT)의 최신 뉴스
Microbot Medical’s LIBERTY System Gains Early Market Traction - TipRanks
Microbot Medical®'s Liberty® endovascular robotic system is now adopted by multiple accounts across key territories including two Access-PVI pivotal clinical trial sites - marketscreener.com
A blood-vessel robot lands 2 trial sites as its rollout expands - Stock Titan
Microbot Medical®’S Liberty® Endovascular Robotic System Is Now Adopted By Multiple Accounts Across Key Territories Including Two Access-Pvi Pivotal Clinical Trial Sites - TradingView
Microbot wins multiple LIBERTY system accounts, including two ACCESS-PVI trial sites - TradingView
Microbot Medical (MBOT) gains new LIBERTY robotic adopters post-SIR - Stock Titan
Microbot Medical®’s LIBERTY® Endovascular Robotic System is - GlobeNewswire
Microbot Medical (NASDAQ:MBOT) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Microbot Medical Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia - marketscreener.com
MBOT Stock Price, Quote & Chart | MICROBOT MEDICAL INC (NASDAQ:MBOT) - ChartMill
Microbot Medical Inc. appoints Alon Tamir as VP Sales EMEA - Indian Pharma Post
Microbot Medical Expands EMEA Leadership for Global Growth - TipRanks
Microbot Medical appoints VP Sales EMEA to drive international commercial readiness - TradingView
Microbot Medical appoints Alon Tamir as VP of sales for EMEA - Investing.com UK
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA) - The Manila Times
Microbot Medical (NASDAQ: MBOT) targets EMEA growth with new VP - Stock Titan
Microbot Medical (MBOT) price target increased by 12.50% to 7.65 - MSN
MBOT Technical Analysis | Trend, Signals & Chart Patterns | MICROBOT MEDICAL INC (NASDAQ:MBOT) - ChartMill
MBOT Earnings History & Surprises | EPS & Revenue Results | MICROBOT MEDICAL INC (NASDAQ:MBOT) - ChartMill
Microbot Medical Inc. (NASDAQ:MBOT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Microbot Medical begins full US launch of LIBERTY system - MSN
Microbot Medical | 8-K: Current report - Moomoo
Microbot Medical | 4: Statement of changes in beneficial ownership of securities-Director Burell Scott R - Moomoo
Microbot Medical (MBOT) Competitive Edge | Q4 2025: Profit Exceeds ViewsMarket Share - Cổng thông tin điện tử tỉnh Lào Cai
MBOT (Microbot Medical Inc.) reports narrower Q4 2025 loss than consensus estimates, shares fall more than two percent.High Interest Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Microbot Medical Highlights Guidelines Supporting LIBERTY Robotic System - TipRanks
Microbot Medical welcomes updated SIR/CIRSE occupational guidelines, cites potential boost to LIBERTY commercial position - TradingView
Radiology safety push may aid Microbot (NASDAQ: MBOT) LIBERTY - Stock Titan
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY - ChartMill
Attachment - GlobeNewswire
How to Manage Microbot Medical (MBOT) Stock Risk (Modest Decline) 2026-04-20Hot Community Stocks - UBND thành phố Hải Phòng
HC Wainwright Analysts Increase Earnings Estimates for MBOT - MarketBeat
Microbot Medical to present at Needham healthcare conference By Investing.com - Investing.com Australia
Microbot Medical Begins Full U.S. Launch of LIBERTY System - Yahoo Finance
Microbot Medical® to Highlight Commercial Achievements Leading t - GuruFocus
Microbot Medical to Highlight Commercial Achievements Leading to the Full Market Release of the LIBERTY Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference - marketscreener.com
Microbot Medical® to Highlight Commercial Achievements - GlobeNewswire
MBOT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Microbot Medical to present at Needham healthcare conference - Investing.com
Microbot Medical to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Microbot Showcases LIBERTY Robotic System Full Release - TipRanks
Microbot to Spotlight LIBERTY Full Market Release, CEO to Present at Needham Conference - TradingView
Microbot Medical (NASDAQ: MBOT) to spotlight LIBERTY robotic system FMR - Stock Titan
Microbot Medical Inc (MBOT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
0.44%
자본화:
|
볼륨(24시간):